FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HCT Type: (check all that apply) 

 
 

gfedcb
Autologous

 
 

 
gfedcb

Allogeneic, unrelated

 
 

 
gfedcb

Allogeneic, related

 

Product type: (check all that apply) 

 
 

gfedcb
Bone marrow

 
 

 
gfedcb

PBSC

 
 

 
gfedcb

Single cord blood unit

 
 

 
gfedcb

Multiple cord blood units

 
 

 
gfedcb

Other product

 
 
Specify:    

 
 

Visit

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 

Indicate which of the following manifestations of the disease were present since the date of the last report:  
 

1  Giant leukocyte granules

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

2  Neutropenia (ANC < 1.0 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

3  Recurrent infections

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

4  Thrombocytopenia (platelets < 100 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

5  Bleeding diathesis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

6  Bleeding from the GI tract

    
 nmlkji

yes  
 nmlkji

no  

 
 

7  Easy bruising

    
 nmlkji

yes  
 nmlkji

no  

 
 

8  Hematuria

    
 nmlkji

yes  
 nmlkji

no  

 
 

9  Oral bleeding

    
 nmlkji

yes  
 nmlkji

no  

  Key Fields 

  Disease Assessment Since the Date of Last Report Questions: 1 - 24

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 6



 
 

10  Recurrent nosebleeds

    
 nmlkji

yes  
 nmlkji

no  

 
 

11  Other bleeding

    
 nmlkji

yes  
 nmlkji

no  

 
 
12  Specify other bleeding:    

 
 

13  Did any clinical neurologic abnormalities persist or develop?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify neurologic dysfunction(s):  
 

14  Abnormal gait

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  Areflexia

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Ataxia and/or other symptoms of cerebellar dysfunction

    
 nmlkji

yes  
 nmlkji

no  

 
 

17  Developmental delay

    
 nmlkji

yes  
 nmlkji

no  

 
 

18  Was the recipient’s IQ tested?

    
 nmlkji

yes  
 nmlkji

no  

 
 
19  Date IQ was tested: __ __ __ __ - __ __- __ __  

 
 

20  IQ test instrument

    
 nmlkji

Kaufman Assessment Battery for Children  

 nmlkji
Raven’s Progressive Matrices  

 nmlkji
Stanford-Binet  

 nmlkji
Wechsler Adult Intelligence Scale  

 nmlkji
Wechsler Intelligence Scale for Children  

 nmlkji
Woodcock-Johnson Tests of Cognitive Abilities  

 
 
21  IQ score:    

 
 

22  Seizures

    
 nmlkji

yes  
 nmlkji

no  

 
 

23  Other neurologic abnormality

    
 nmlkji

yes  
 nmlkji

no  

 
 
24  Specify other neurologic abnormality:    

 
 

25  Did the recipient develop features of an accelerated phase since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
26  Number of accelerated phases recorded:    

 
 

27  Date first accelerated phase detected

    (in this reporting period)  

 nmlkji
Known  

 nmlkji
Unknown  

 
 
28  Date first accelerated phase was detected: __ __ __ __ - __ __- __ __  

  Accelerated Phase (AP) Questions: 25 - 51

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 6



 
 

29  Abnormal CSF

    (WBC >5 cells/µL, elevated protein)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

30  Abnormal liver function

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

31  Anemia

    (Hgb <10 g/dL)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

32  Cytomegalovirus (CMV)

    (associated with accelerated phase)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

33  Epstein-Barr virus (EBV)

    (associated with accelerated phase)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

34  Other viral infection associated with accelerated phase

    (not CMV or EBV)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 
35  Specify other infection:    

 
 

36  Dense bodies (delta granules) on electron micrograph (EM) of platelets

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

37  Elevated triglycerides

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

38  Fevers

    (> 38.5° C or > 101.3° F for > 7 days)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

39  Hemophagocytosis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

40  Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

41  Hyperferritinemia

    (serum ferritin > 500 ng/mL or > 500 µg/dL) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

42  Hypofibrinogenemia

    (serum fibrinogen < 150 mg/dL or < 1.5 g/L or < 4.4 µmol/L) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

43  Hyponatremia

    (serum sodium < 135 mg/dL)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

44  Lymphadenopathy

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

45  CSF lymphocytosis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 6



 
 

46  Neurologic dysfunction

    (e.g. seizures, meningitis signs)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 
 

47  Neutropenia (ANC < 1.0 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

48  Splenomegaly (spleen palpable > 3 cm below left costal margin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

49  Thrombocytopenia (platelets < 100 x 109 /L)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

50  Other feature associated with accelerated phase

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
51  Specify other feature:    

 
 

52  Was therapy given?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify therapy given:  
 

53  Acyclovir

    
 nmlkji

yes  
 nmlkji

no  

 
 

54  Antithymocyte globulin (ATG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Cyclosporine (CSA, Neoral, Sandimmune)

    
 nmlkji

yes  
 nmlkji

no  

 
 

57  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  Ganciclovir (DHPG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

59  Intrathecal methotrexate (IT MTX)

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  Intravenous immune globulin (IVIG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

61  Interferon-α (Intron, Roferon) (includes PEG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  Rituximab (Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
64  Specify other therapy:    

  Post-HCT Therapy Questions: 52 - 64

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 6



 
 

65  Cytotoxic T-cell activity

    
 nmlkji

Absent  (< 10% of control) 

 nmlkji
Low  (10–30% of control) 

 nmlkji
Normal  (> 30% of control) 

 nmlkji
Not done  

 
 

66  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
67  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

68  Degranulation of cytolytic lymphocytes (CD107a expression)

    
 nmlkji

Absent  (< 10% of control) 

 nmlkji
Low  (10–30% of control) 

 nmlkji
Normal  (> 30% of control) 

 nmlkji
Not done  

 
 

69  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
70  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

71  Granulocyte chemotaxis

    
 nmlkji

Absent  (< 10% of control) 

 nmlkji
Low  (10-30% of control) 

 nmlkji
Normal  (>30% of control) 

 nmlkji
Not done  

 
 

72  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
73  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

74  Natural killer cell activity

    (against K562 cells)  

 nmlkji
Absent  (<10% of control) 

 nmlkji
Low  (10-30% of control) 

 nmlkji
Normal  (>30% of control) 

 nmlkji
Not done  

 
 

75  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
76  Date sample collected: __ __ __ __ - __ __- __ __  

  Current Assessment of Immunologic Function Post-HCT Questions: 65 - 82

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 6



 
 

77  Phytohemagglutinin (PHA)

    
 nmlkji

Absent  (<10% of control) 

 nmlkji
Low  (10-30% of control) 

 nmlkji
Normal  (>30% of control) 

 nmlkji
Not done  

 
 

78  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
79  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

80  Platelet aggregation

    
 nmlkji

Absent  (<10% of control)  

 nmlkji
Low  (10-30% of control) 

 nmlkji
Normal  (>30% of control) 

 nmlkji
Not done  

 
 

81  Date sample collected

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
82  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

83  What is the current disease status?

    
 nmlkji

No prior accelerated phase  

 nmlkji
In remission from accelerated phase  

 nmlkji
In accelerated phase  

 nmlkji
Unknown  

 
 
84  Date assessed: __ __ __ __ - __ __- __ __  

 
 
First Name:    

 
 
Last Name:    

 
 
E-mail address:    

 
 
Date: __ __ __ __ - __ __- __ __  

  Disease Status at the Time of Evaluation for This Reporting Period Questions: 83 - 84

Form 2156 R1.0: Pigmentary Dilution Disorder (PDD) Post-HCT Data  
Center:  CRID: 

        CIBMTR Form 2156 revision 1.0 last updated October 2013  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 6